BIOPHTA

📍 Paris, France🗓 Founded 2020👥 9 employees💰 Last funded Apr 2024

Pharmaceutical Manufacturing 🌐 biophta.com

World Health Organization evaluates between 200 and 300 million, the number of people who are visually impaired by diseases against which pharmaceutical treatments are however existing. Many of these conditions have in common to cause permanent vision loss if they are not treated consistently. The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments. We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery. Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release. BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.

Total investors

Early stage

Mid stage

Late stage

2020

Founded